These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 21729712)
1. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Bruno RD; Vasaitis TS; Gediya LK; Purushottamachar P; Godbole AM; Ates-Alagoz Z; Brodie AM; Njar VC Steroids; 2011 Nov; 76(12):1268-79. PubMed ID: 21729712 [TBL] [Abstract][Full Text] [Related]
2. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. DeVore NM; Scott EE Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943 [TBL] [Abstract][Full Text] [Related]
3. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482 [TBL] [Abstract][Full Text] [Related]
4. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836 [TBL] [Abstract][Full Text] [Related]
5. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. Soifer HS; Souleimanian N; Wu S; Voskresenskiy AM; Collak FK; Cinar B; Stein CA J Biol Chem; 2012 Feb; 287(6):3777-87. PubMed ID: 22174412 [TBL] [Abstract][Full Text] [Related]
6. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590 [TBL] [Abstract][Full Text] [Related]
7. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. Njar VC; Brodie AM J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066 [TBL] [Abstract][Full Text] [Related]
8. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635 [TBL] [Abstract][Full Text] [Related]
9. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. Bird IM; Abbott DH J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414 [TBL] [Abstract][Full Text] [Related]
10. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron. Song D; Zhang J; Wang Y; Hu J; Xu S; Xu Y; Shen H; Wen X; Sun Z J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391 [TBL] [Abstract][Full Text] [Related]
11. Agents that target androgen synthesis in castration-resistant prostate cancer. Ferraldeschi R; de Bono J Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755 [TBL] [Abstract][Full Text] [Related]
12. 17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Bruno RD; Gover TD; Burger AM; Brodie AM; Njar VC Mol Cancer Ther; 2008 Sep; 7(9):2828-36. PubMed ID: 18790763 [TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Salem M; Garcia JA Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537 [TBL] [Abstract][Full Text] [Related]
14. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. Purushottamachar P; Godbole AM; Gediya LK; Martin MS; Vasaitis TS; Kwegyir-Afful AK; Ramalingam S; Ates-Alagoz Z; Njar VC J Med Chem; 2013 Jun; 56(12):4880-98. PubMed ID: 23713567 [TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. Nandha R J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354 [TBL] [Abstract][Full Text] [Related]
16. Abiraterone in prostate cancer: a new angle to an old problem. Stein MN; Goodin S; Dipaola RS Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619 [TBL] [Abstract][Full Text] [Related]
17. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823 [TBL] [Abstract][Full Text] [Related]